INmune Bio (NASDAQ:INMB) Earns Outperform Rating from Analysts at Raymond James
Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $18.00 target price on the stock. Separately, Scotiabank started coverage on shares of INmune Bio in a research note on Thursday, August 22nd. […]
More Stories
Insider Selling: Harvey Norman Holdings Limited (ASX:HVN) Insider Sells 2,514 Shares of Stock
Harvey Norman Holdings Limited (ASX:HVN – Get Free Report) insider Kay Page sold 2,514 shares of the company’s stock in...
Roth Mkm Cuts MGP Ingredients (NASDAQ:MGPI) Price Target to $60.00
MGP Ingredients (NASDAQ:MGPI – Get Free Report) had its target price decreased by Roth Mkm from $65.00 to $60.00 in...
Helius Medical Technologies, Inc. Announces First PoNS System Sale to VA Healthcare SystemOn December 23, 2024, Helius Medical Technologies, Inc. (NASDAQ:HSDT) disclosed its successful sale of the first Portable Neuromodulation Stimulator (PoNS) Syst
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) saw some unusual options trading on Monday. Stock traders bought 13,040 call...
Microvast (NASDAQ:MVST) Shares Gap Up – What’s Next?
Microvast Holdings, Inc. (NASDAQ:MVST – Get Free Report) gapped up prior to trading on Monday . The stock had previously...
Direxion Daily TSLA Bull 2X Shares (NASDAQ:TSLL) Shares Gap Up – Time to Buy?
Direxion Daily TSLA Bull 2X Shares (NASDAQ:TSLL – Get Free Report)’s share price gapped up prior to trading on Monday...